Greater Asia News
Singapore’s Thomson Medical buys Vietnam’s FV Hospital
SGX Mainboard-listed healthcare group Thomson Medical Group (TMG) has agreed to acquire Vietnam's FV Hospital for up to $381.4 million,.
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Zolbetuximab
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Medicines Agency (EMA) has accepted for regulatory review the company's marketing authorization application (MAA) for zolbetuximab.
Novotech Announced as Finalist for Asia Pacific Cell & Gene Therapy CRO Excellence Awards 2023
Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities is a finalist in the Asia Pacific Cell & Gene Therapy Awards 2023.
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that its Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (USFDA).
JEOL: Release of Scanning Electron Microscopes JSM-IT710HR/JSM-IT210
JEOL Ltd. (TOKYO:6951) (President & CEO Izumi Oi) announces the release of scanning electron microscopes JSM-IT710HR/JSM-IT210 on July 23, 2023.
Eisai to Present the Latest Alzheimer’s Disease Pipeline and Research, including Lecanemab and Anti-MTBR TAU Antibody E2814, at the Alzheimer’s Association International Conference 2023
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI®), and the company's investigational anti-MTBR** tau antibody, E2814, at the Alzheimer's Association International Conference (AAIC).
Samsung Bioepis Releases its Second US Biosimilar Market Report
Samsung Bioepis Co., Ltd. today released the second edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States.
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration and drug development in pulmonary fibrosis.
Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results
Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2023 on Friday, 4 August 2023.
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT’s Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David Kirn, MD, "4DMT") today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees.
